Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 1/2 4Phase 2 2Phase EARLY_PHASE1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 5CNS 5Sarcoma 3Head & Neck 3Breast 2Tumor-Agnostic 1Plasma cell 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Breast Neoplasms 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × poly ICLC × Breast × Clear all
NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01984892 2018-01-23

Hiltonol

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
8 enrolled 4 charts
BreastDermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡